The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature

[1]  J. Peter,et al.  Institute for Clinical and Economic Review , 2021, The Right Price.

[2]  J. Salcedo,et al.  Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease , 2021, Scientific Reports.

[3]  L. B. Herity,et al.  Voxelotor: A Novel Treatment for Sickle Cell Disease , 2020, The Annals of pharmacotherapy.

[4]  N. Shah,et al.  Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study , 2020, Journal of health economics and outcomes research.

[5]  A. Rizio,et al.  The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease , 2020, Quality of Life Research.

[6]  S. Ballas.  The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease , 2020, Mediterranean journal of hematology and infectious diseases.

[7]  E. Benz.  Cure Sickle Cell Initiative , 2019 .

[8]  D. Lubeck,et al.  Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease , 2019, JAMA network open.

[9]  N. Shah,et al.  Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study , 2019, Health and Quality of Life Outcomes.

[10]  LaTasha H Lee,et al.  Reducing Health Care Disparities in Sickle Cell Disease: A Review , 2019, Public health reports.

[11]  S. Rivella,et al.  Gene therapy of hemoglobinopathies: progress and future challenges. , 2019, Human molecular genetics.

[12]  C. Harrison.  First gene therapy for β-thalassemia approved , 2019, Nature Biotechnology.

[13]  K. Maitland,et al.  The epidemiology of sickle cell disease in children recruited in infancy in Kilifi, Kenya: a prospective cohort study , 2019, The Lancet. Global health.

[14]  L. Hsu,et al.  Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment , 2019, International journal of neonatal screening.

[15]  L. Garrison,et al.  Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold. , 2019, Journal of managed care & specialty pharmacy.

[16]  I. Rudan,et al.  The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis , 2018, Journal of global health.

[17]  Jason R. Hodges,et al.  Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood , 2018, Pediatric blood & cancer.

[18]  I. Hambleton,et al.  Causes of death and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from birth , 2018, PloS one.

[19]  Louis P Garrison,et al.  Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  Fredrik Norström,et al.  On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review , 2018, Global health action.

[21]  S. Azar,et al.  Sickle Cell Disease: A Brief Update. , 2017, The Medical clinics of North America.

[22]  R. Ware,et al.  Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. , 2017, Blood.

[23]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[24]  J. Howard.  Sickle cell disease: when and how to transfuse. , 2016, Hematology. American Society of Hematology. Education Program.

[25]  C. U. Uyl‐de Groot,et al.  Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  A. Habib,et al.  Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis , 2016, BMC Health Services Research.

[27]  Iván Castilla-Rodríguez,et al.  Cost-effectiveness analysis of newborn screening for sickle-cell disease in Spain , 2016 .

[28]  M. Telen.  Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. , 2016, Blood.

[29]  N. Kassebaum,et al.  A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola. , 2015, The Journal of pediatrics.

[30]  Abdullahi O. Abdulkadri,et al.  Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis , 2015, Pediatric blood & cancer.

[31]  R. Ware,et al.  Hydroxyurea therapy for sickle cell anemia , 2015, Expert opinion on drug safety.

[32]  Zhezhen Jin,et al.  Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  S. Griffin,et al.  Distributional Cost-Effectiveness Analysis , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  P. Carey.  Addressing the global health burden of sickle cell disease. , 2014, International health.

[35]  A. Tobian,et al.  Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease , 2014, Transfusion.

[36]  Joshua D Stein,et al.  Use of health care claims data to study patients with ophthalmologic conditions. , 2014, Ophthalmology.

[37]  A. Tobian,et al.  Cost‐effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients , 2014, Transfusion.

[38]  M. Sculpher,et al.  Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial , 2013, European journal of haematology.

[39]  S. Shenoy.  Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions , 2013, Therapeutic advances in hematology.

[40]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement , 2013, PharmacoEconomics.

[41]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.

[42]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[43]  J. Karnon,et al.  Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.

[44]  A. Busca,et al.  In vivo T‐cell depletion with pretransplant low‐dose antithymocyte globulin is associated with reduced transplant‐related mortality and improved clinical outcome in patients receiving allogeneic hematopoietic stem cell transplantation from unrelated and partially matched related donors , 2011, American journal of hematology.

[45]  M. Treadwell,et al.  Transition from pediatric to adult care in sickle cell disease: Establishing evidence‐based practice and directions for research , 2011, American journal of hematology.

[46]  Winfred C. Wang,et al.  Health‐related quality of life in children with sickle cell disease: A report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium , 2010, Pediatric blood & cancer.

[47]  S. O’Brien,et al.  Decision Analysis of Treatment Strategies in Children With Severe Sickle Cell Disease , 2009, Journal of pediatric hematology/oncology.

[48]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[49]  A. Hartzema,et al.  The cost of health care for children and adults with sickle cell disease , 2009, American journal of hematology.

[50]  J. Moskowitz,et al.  Caregiving time in sickle cell disease: Psychological effects in maternal caregivers , 2007, Pediatric blood & cancer.

[51]  C. Miaskowski,et al.  Changes in sleep, food intake, and activity levels during acute painful episodes in children with sickle cell disease. , 2006, Journal of pediatric nursing.

[52]  R T Brown,et al.  Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease , 2001, Neurology.

[53]  P. Lane.  Sickle cell disease. , 1996, Pediatric clinics of North America.

[54]  G. Serjeant.  The natural history of sickle cell disease. , 1982, Cold Spring Harbor perspectives in medicine.

[55]  Y. Dundar,et al.  The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. , 2012, Health technology assessment.

[56]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[57]  T. Walley,et al.  Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. , 2009, Health technology assessment.